PBLS — PARABILIS MEDICINES INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 82 SEC-registered investment managers reported holding PBLS (PARABILIS MEDICINES INC) in their latest 13F filings, with a combined reported value of $2.78B across 102.19M shares. Ownership is concentrated: the five largest holders account for 55.0% of reported value and the top ten for 73.5%.
Compared with the prior quarter, 82 opened new positions. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
Major shareholders of PARABILIS MEDICINES INC (PBLS) include RA CAPITAL MANAGEMENT, L.P., Fidelity Management & Research (FMR), ARCH Venture Management, LLC, ranked by reported 13F value among the 124 institutional holders on this page.
PBLS is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q3 2026 | 77 | 36.15M | $1.15B | +9.3% |
| Q2 2026 | 82 | 102.19M | $2.78B | — |
Over the 2 quarters shown, institutional share counts decreased 65% in aggregate (Q2 2026 → Q3 2026).
Top Institutional Holders (Q3 2026) — 25 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 10.87M | $336.59M | 0.01% | Add | |
| 4.92M | $158.85M | 0.18% | Hold | |
| 4.17M | $134.54M | 74.90% | Hold | |
| 2.99M | $96.62M | 2.29% | Hold | |
| 2.79M | $90.11M | 0.00% | New | |
| 1.58M | $51.10M | 0.00% | Add | |
| 1.56M | $50.25M | 0.00% | Add | |
| 1.54M | $49.68M | 2.04% | Hold | |
| 1.06M | $33.91M | 0.00% | Add | |
| 1.00M | $32.46M | 0.00% | Add | |
| 757.79K | $24.47M | 0.00% | New | |
| 445.36K | $14.38M | 0.02% | Hold | |
| 449.18K | $13.64M | 0.00% | Add | |
| 365.42K | $11.80M | 0.00% | Add | |
| 248.60K | $8.03M | 0.00% | Add | |
| 245.59K | $7.93M | 0.01% | Hold | |
| 211.82K | $6.84M | 0.00% | Add | |
| 202.80K | $6.55M | 0.01% | New | |
| 102.38K | $3.31M | 0.00% | New | |
| 90.79K | $2.93M | 0.00% | New | |
| 61.70K | $1.99M | 0.00% | Add | |
| 52.07K | $1.68M | 0.00% | Add | |
| 50.15K | $1.62M | 0.00% | New | |
| 45.11K | $1.46M | 0.00% | New | |
| 43.90K | $1.42M | 0.00% | New |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q2 2026 — 25 funds
New Positions (Q2 2026)
- RA CAPITAL MANAGEMENT, L.P. 28.93M sh · $791.91M
- Fidelity Management & Research (FMR) 10.29M sh · $281.71M
- ARCH Venture Management, LLC 6.41M sh · $175.52M
- venBio Partners LLC 5.27M sh · $144.15M
- Alphabet Inc. 4.92M sh · $134.65M
- Nextech Invest Ltd. 4.66M sh · $127.63M
- Cormorant Asset Management, LP 4.62M sh · $126.33M
- REGENERON PHARMACEUTICALS, INC. 4.17M sh · $114.04M
- Siren, L.L.C. 2.99M sh · $81.90M
- Farallon Capital Management 2.37M sh · $64.82M
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.37M sh · $64.82M
- Jupiter Topco LLC 2.30M sh · $62.71M
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q3 2026 | Q2 2026 |
|---|---|---|
| Fidelity Management & Research (FMR) | 10.87M | 10.29M |
| Alphabet Inc. | 4.92M | 4.92M |
| REGENERON PHARMACEUTICALS, INC. | 4.17M | 4.17M |
| Siren, L.L.C. | 2.99M | 2.99M |
| BlackRock Inc | 2.79M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.58M | 1.30M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.56M | 1.16M |
| GENERAL ATLANTIC, L.P. | 1.54M | 1.54M |
| JPMorgan Chase & Co | 1.06M | 1.04M |
| Geode Capital Management | 1.00M | 99.36K |
| STATE STREET CORP | 757.79K | — |
| Marshall Wace | 445.36K | 445.36K |
| Franklin Resources | 449.18K | 381.49K |
| MFS Investment Management | 365.42K | 295.96K |
| VANGUARD FIDUCIARY TRUST CO | 248.60K | 27.80K |
| FEDERATED HERMES, INC. | 245.59K | 246.20K |
| UBS Group AG | 211.82K | 38.70K |
| Manulife Financial | 202.80K | — |
| BNY Mellon | 102.38K | — |
| Nuveen, LLC | 90.79K | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details
FAQ
Which funds hold PBLS?
As of 2026-Q2, 82 institutional funds reported holding PBLS (PARABILIS MEDICINES INC) in SEC 13F filings, with a combined reported value of $2.78B.
How many shares of PBLS do institutions own?
13F filers reported 102.19M shares of PBLS, worth $2.78B in aggregate at the end of 2026-Q2.
Is institutional ownership of PBLS rising or falling?
No prior-quarter baseline is available for a directional read.
Who are the top institutional holders of PBLS?
The largest 13F holders are RA CAPITAL MANAGEMENT, L.P., Fidelity Management & Research (FMR), ARCH Venture Management, LLC, Alphabet Inc., venBio Partners LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of PARABILIS MEDICINES INC?
The major shareholders of PARABILIS MEDICINES INC (PBLS) by reported 13F value are RA CAPITAL MANAGEMENT, L.P., Fidelity Management & Research (FMR), ARCH Venture Management, LLC, Alphabet Inc., venBio Partners LLC, among 124 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.